Reference record
Safety and Effectiveness of EV-Pure + WJ-Pure Treatment on Pulmonary Fibrosis Secondary to Covid-19
Vitti Labs, LLC
First Published (first received 2022 May 24)ClinicalTrials.gov (https://clinicaltrials.gov/show/NCT05387239)
Trial registry recordNo Results
The COVID-induced fibrotic lung damage continues long after viral infection has subsided and
is exhibited by severe respiratory pathology and concomitant symptoms. The long-lasting
sequelae in patients who have recovered from severe COVID indicate that there is a 30% chance
of developing a persistent respiratory system pathology and a 10% chance of developing a
severe pathology. The symptoms of lung fibrosis include a severe disruption of respiration,
reduction of exercise tolerance, and concomitant development of persistent fibrotic lung
damage. This study intends to evaluate benefits of a combination of WJPure and EVPure in
Covid-19 patients exhibiting pulmonary fibrosis